



Michigan Vascular Center

BEST - CLI TRIAL UPDATE

Michigan Vascular Study Group and BMC2

November 9, 2017

Robert G. Molnar, MD
Michigan Vascular Center

**Since
1963**



Michigan Vascular Center



BEST-CLI

Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia

Sponsored by the National Heart Lung and Blood Institute



Since
1963



Chronic Limb Ischemia - CLI

- Pain at rest
 - Forefoot, leg/ calf
- Ulcers, gangrene





Critical Limb Ischemia (CLI) - Impact

- CLI is treated with measures to improve limb perfusion
- In the absence of revascularization, limb amputation rate in patients with CLI approaches 40%

Hirsch AT et al. J Am Coll Cardiol 2006;47:1239-1312



Trial Overview

- Prospective, randomized, multicenter, open label superiority trial
- **2,100** patients at **120** clinical sites in United States and Canada
- 4-year trial with each patient having minimum of 2 year follow-up
- Funded by National Heart Lung and Blood Institute at level of \$24,990,000



Trial Overview

- Inclusion Criteria
 - Male or Female age 18 or older
 - Infrainguinal PAOD
 - CLI defined as arterial insufficiency with gangrene, ulceration or rest pain consistent with Rutherford categories 4-6
 - Candidate for both endovascular and open infrainguinal revascularization
 - Adequate aortoiliac inflow
 - Popliteal, tibial or pedal revascularization target which can support a distal anastomosis of a surgical bypass
 - Willingness to comply with protocol and follow up.



Trial Overview

- Exclusion Criteria
 - Popliteal aneurysm > 2cm in index limb
 - Life expectancy less than 2 years
 - Excessive risk for surgical bypass
 - Planned above-ankle amputation within 4 weeks of index procedure
 - Active vasculitis, Buerger's disease, or acute limb-threatening disease
 - Any prior index limb infrainguinal stenting or stent grafting associated with significant restenosis within 1 cm of the stent or stent-graft, unless the occlusion/restenosis site is outside of the treatment zone
 - Any of the following procedures performed on the index limb within 3 months: pta, atherectomy, stent, bypass with either vein or prosthetic



Trial Overview

- Exclusion Criteria continued:
 - Open surgical inflow procedure within 6 weeks prior to enrollment
 - Current chemotherapy or radiation
 - Absolute contra-indication to iodinated contrast
 - Pregnancy or lactation
 - Administration of an investigational drug for PAOD within 30 days
 - Participation in a clinical trial within 30 days
 - Prior enrollment or randomization into BEST-CLI



Trial Objective

BEST Trial Aim

To compare treatment efficacy, functional outcomes and cost in patients with CLI and infrainguinal PAD undergoing best **open surgical** or best **endovascular** revascularization



Patient Population

Patients with CLI and infrainguinal PAD who are candidates for **both** open surgical infrainguinal revascularization **and** endovascular treatment, in the eyes of the ~~individual investigator~~ CLI team



Map of BEST-CLI Sites





Enrollment Update

To date (9/14/17)

- First patient randomized 8/28/14
- 158 of 171 sites activated
- 1072 subjects randomized

Top 5 enrolling sites:

#1160 Keck Medical Center of USC - 52 subjects

#1258 Boston Medical Center - 50 subjects


#1238 Univ. of Massachusetts – 31 subjects

#1273 Univ. Florida (Gainesville) – 23 subjects

#1309 Iowa Heart – 22 subjects



Enrollment Goals



Milestones:
1,188 Subjects
by 9/30/17
2,100 Subjects
by 8/31/18



Top 10 Reasons for Screen Failures

50th

Anniversary
1963-2013

Michigan Vascular Center

- 909 = Excessive risk for surgical bypass
- 591= Pt doesn't want to be part of research
- 568= Pt doesn't want surgical procedure
- 523= Inadequate aortoiliac inflow
- 509= Disallowed index limb proc in prior 6mo
- 470= Inadequate revascularization target
- 390= Occlusive disease on imaging not severe enough
- 371= Procedure performed on index limb within 3 months prior to enrollment
- 348= Significant restenosis of prior stent/graft
- 316= Other Reasons

Since
1963



Obstacles to enrollment

- Convincing partners to review and enroll their patients
- Introducing study to patients is difficult given that both open and endo are available as standard of care.
- Personal bias
- Lack of site specific plan for screening process and patient flow